In Austin, startups come and go with promises of disruption, but every so often a team shows up with tech that doesn’t just clean instruments, it disinfects old thinking. That’s Lumaegis, Inc. Founded in 2018, this company is led by CEO and President John S. Morreale, CTO Dr. Sudhir Subramanya, and Chief Innovation Officer Matthijs Keuper. These aren’t rookies, they’re the same kind of minds that helped drive the LED revolution, which the Department of Energy credits with saving 570M tons of CO2. Now they’re aiming that light at the sterilization industry, and the result is RadBox, a device that makes the traditional autoclave look like it belongs in a museum.
On August 26, 2025, Lumaegis closed a $200K pre-seed round, led by a global strategic partner already deep in sterilization. This raise is part of a $1.5M convertible note, with roughly $300K already committed through angels and venture sources. The plan for this money isn’t vague, it’s going straight into building production-ready units, completing FDA, UL/CE, and durability testing, with FDA-mandated trials beginning before year-end. No endless fundraising treadmill here, just a sprint to regulatory clearance and commercial launch.
RadBox carries FDA De Novo classification, a designation reserved for tech so novel that no predicate device exists. It sterilizes in under six mins using UV-C and infrared LEDs, compared to the 85–90 mins required by steam sterilizers. The math writes itself: three times the productivity, 75% smaller footprint, 80% less power consumption, and zero water. For a clinic, that translates to a $25K annual savings per unit. In lab tests, RadBox hit a six-log kill against Bacillus pumilus in under 3 mins, the benchmark bug for radiative sterilization. That’s speed, safety, and science converging in one box.
The market is hungry. Dental sterilization sits at $2B today and is projected to hit $3.5B by 2033, with nearly 68% controlled by clinics in North America. Lumaegis already has its first major customer, also an investor, lined up for over 2,000 units. Add in Letters of Intent from early dental partners who helped shape the device, and the road to 2026 first sales is paved with demand.
From there, the strategy is precision. Direct-to-dental customers to refine, followed by scaling into veterinary and research markets. Distribution will lean on players like Darby, Benco Dental, and Safco Dental, alongside fast-growing Dental Service Organizations. The company projects cash flow positive operations within 27 months of first sales.
John S. Morreale brings aerospace and supply chain rigor, Dr. Sudhir Subramanya brings deep medical and sustainability insight, and Matthijs Keuper brings applied physics expertise forged in Philips labs. They’re betting the same technology that transformed how the world is lit will now transform how it is sterilized.
Funding secured. Regulatory milestones in motion. Customers ready. Lumaegis isn’t flashing signals, it’s setting the standard for faster, cleaner, more sustainable infection control.
